Patent: 10,953,101
✉ Email this page to a colleague
Summary for Patent: 10,953,101
| Title: | Glycotargeting therapeutics |
| Abstract: | Several embodiments of the present disclosure relate to therapeutic compositions configured to target the liver of a subject and that are useful in the treatment or prevention of one or more of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent. In several embodiments, the compositions are configured to target the liver and deliver antigens to which tolerance is desired. In several embodiments, the compositions are configured for clearance of a circulating protein or peptide or antibody associated with one or more of the above-mentioned maladies. Methods and uses of the compositions for induction of immune tolerance are also disclosed herein. |
| Inventor(s): | Jeffrey A. Hubbell, David Scott Wilson |
| Assignee: | Ecole Polytechnique Federale de Lausanne EPFL |
| Application Number: | US15/925,628 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,953,101
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Biogen Inc. | TYSABRI | natalizumab | Injection | 125104 | November 23, 2004 | ⤷ Get Started Free | 2038-03-19 |
| Sanofi-aventis U.s. Llc | ADLYXIN | lixisenatide | Injection | 208471 | July 27, 2016 | ⤷ Get Started Free | 2038-03-19 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 10,953,101
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2017046652 | ⤷ Get Started Free |
| World Intellectual Property Organization (WIPO) | 2015140648 | ⤷ Get Started Free |
| United States of America | 2025295743 | ⤷ Get Started Free |
| >Country | >Patent Number | >Estimated Expiration |
